When should plasma brain natriuretic peptide (BNP) be measured, and what BNP level thresholds indicate the likelihood of acute or chronic heart failure?

When to Measure BNP and Diagnostic Thresholds

Measure plasma BNP or NT-proBNP immediately when evaluating any patient presenting with acute dyspnea or suspected heart failure in the emergency department or acute care setting, as these biomarkers provide rapid and accurate exclusion of heart failure with excellent negative predictive values. 1

Diagnostic Thresholds for Acute Heart Failure

Rule-Out (Exclusion) Thresholds

When evaluating patients with acute dyspnea in the emergency department:

• BNP <100 pg/mL excludes acute HF with 95% sensitivity and 94% negative predictive value 2, 1
• NT-proBNP <300 pg/mL excludes acute HF with 99% sensitivity and 98% negative predictive value 1

These thresholds are exceptionally reliable for ruling out acute heart failure, meaning values below these cutoffs make HF highly unlikely 1.

Rule-In (Inclusion) Thresholds for Acute HF

For diagnosing probable acute heart failure in symptomatic patients:

BNP:

• >100 pg/mL indicates probable acute HF 2, 1

NT-proBNP (age-adjusted for better specificity): 2, 3

• >450 pg/mL for age <50 years
• >900 pg/mL for age 50-75 years
• >1,800 pg/mL for age >75 years

Diagnostic Thresholds for Chronic Heart Failure

Rule-Out Thresholds

• BNP <35 pg/mL excludes chronic HF 2
• NT-proBNP <125 pg/mL excludes chronic HF 2

Enrollment/Risk Stratification Thresholds

For identifying patients with chronic HF who warrant closer monitoring or enrollment in clinical trials:

HFpEF (preserved ejection fraction):

• BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL 2

HFrEF (reduced ejection fraction):

• BNP ≥150 pg/mL or NT-proBNP ≥600 pg/mL 2

For higher-risk patients requiring more intensive management:

• BNP >400 pg/mL or NT-proBNP >900 pg/mL 2

Critical Adjustments for Special Populations

The 2020 JACC Heart Failure position paper provides essential guidance on threshold adjustments 2:

Atrial Fibrillation

• Increase thresholds by 20-30% (natriuretic peptides are elevated in AF independent of HF) 2

Obesity (BMI ≥30 kg/m²)

• Lower thresholds by 20-30% (adipose tissue suppresses BNP production; use ~50 pg/mL for BNP) 2, 3

Black Patients

• Lower thresholds by 20-30% to avoid false negatives and exclusion from appropriate care 2

Elderly Patients (>75 years)

• Raise thresholds by 20-30% (age-related elevation occurs) 2

Renal Dysfunction

• Both BNP and NT-proBNP are significantly elevated in renal dysfunction even without HF 4, 5
• Interpret elevated values cautiously; echocardiography becomes essential for confirmation 4

Patients on Sacubitril/Valsartan (ARNI)

• Avoid using BNP for monitoring treatment response due to variable assay responses to neprilysin inhibition 2, 5
• NT-proBNP remains reliable as it is not affected by neprilysin inhibition 2
• BNP can still be used for initial diagnosis and risk stratification 2

Key Clinical Pitfalls

Specificity is variable across all thresholds—elevated natriuretic peptides indicate "cardiorenal distress" but do not confirm HF 4. Always obtain echocardiography to confirm structural/functional cardiac abnormalities when natriuretic peptides are elevated 1, 4.

Conditions that elevate BNP/NT-proBNP without primary HF include: acute coronary syndromes, pulmonary embolism, sepsis, hyperthyroidism, and significant valvular disease 6, 5. These elevations still indicate ventricular dysfunction and worse prognosis 6, 7.

The current BNP assays measure both active BNP and inactive proBNP, which can lead to overestimation in certain conditions like macro-proBNPemia 5. NT-proBNP assays have less interassay variability and may be more reliable in complex cases 2.

Practical Algorithm

1. Measure BNP or NT-proBNP in all patients with acute dyspnea or suspected HF
2. If below rule-out threshold → HF excluded, pursue alternative diagnoses
3. If above rule-in threshold → Proceed immediately to echocardiography
4. Adjust interpretation based on age, renal function, obesity, AF, and medications
5. Confirm diagnosis with imaging; never rely on natriuretic peptides alone for definitive diagnosis